Evidence map›Paper›PMID 38274345›Full record

ArticleExperimental and therapeutic medicine2024

Long‑term control in a patient with lung adenocarcinoma, nonbacterial thrombotic endocarditis and multiple systemic emboli: A case report.

Takeshi Kawakami, Yuika Sasatani, Sachie Hasegawa, Gen Ohara, Shinichiro Okauchi, Manato Taguchi, Eiji Ojima, Hiroaki Satoh, Nobuyuki Hizawa

Open access · diamondAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Experimental and therapeutic medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
0.4field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it, 1 citations in OpenAlex.

  1. Pooled it
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Takeshi KawakamiDivision of Respiratory Medicine, University of Tsukuba Hospital, University of Tsukuba, Tsukuba, Ibaraki 305-8576, Japan.
Yuika SasataniDivision of Respiratory Medicine, Mito Medical Center, University of Tsukuba-Mito Kyodo General Hospital, Mito, Ibaraki 310-0015, Japan.
Sachie HasegawaDivision of Respiratory Medicine, University of Tsukuba Hospital, University of Tsukuba, Tsukuba, Ibaraki 305-8576, Japan.
Gen OharaDivision of Respiratory Medicine, Mito Medical Center, University of Tsukuba-Mito Kyodo General Hospital, Mito, Ibaraki 310-0015, Japan.
Shinichiro OkauchiDivision of Respiratory Medicine, Mito Medical Center, University of Tsukuba-Mito Kyodo General Hospital, Mito, Ibaraki 310-0015, Japan.
Manato TaguchiDivision of Respiratory Medicine, University of Tsukuba Hospital, University of Tsukuba, Tsukuba, Ibaraki 305-8576, Japan.
Eiji OjimaDivision of Cardiology, Mito Medical Center, University of Tsukuba-Mito Kyodo General Hospital, Mito, Ibaraki 310-0015, Japan.
Hiroaki SatohDivision of Respiratory Medicine, Mito Medical Center, University of Tsukuba-Mito Kyodo General Hospital, Mito, Ibaraki 310-0015, Japan.
Nobuyuki HizawaDivision of Respiratory Medicine, University of Tsukuba Hospital, University of Tsukuba, Tsukuba, Ibaraki 305-8576, Japan.
National Hospital Organization Mito Medical Center · JPUniversity of Tsukuba Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Systemic emboli are not uncommon in patients with advanced non-small cell lung cancer. The present study describes a rare case of long-term control in a patient with lung adenocarcinoma, nonbacterial thrombotic endocarditis and multiple systemic emboli. Briefly, a 56-year-old man was diagnosed with metastatic lung adenocarcinoma and was treated with pembrolizumab, which was discontinued due to the appearance of a pulmonary immune-related adverse event. During the clinical course, the patient developed pseudo-progression of a brain tumor, repeated thromboembolism in multiple organs and a small vegetation attached to the aortic valve. These lesions were controlled with apixaban after heparin therapy for >3 years. Lung cancer was subsequently treated with pemetrexed and bevacizumab; however, this treatment was terminated due to a complete response and the patient's request to discontinue treatment. More than 3 years have passed since the diagnosis of lung adenocarcinoma, and the patient has been followed up at the hospital without signs of cancer recurrence. Although unusual, the patient's course may provide useful suggestions for the treatment of other patients with a similar evolution.

Indexed as

immune checkpoint inhibitorlung adenocarcinomanonbacterial thrombotic endocarditispembrolizmabsystemic emboli

Identifiers

PMID38274345
PMCPMC10809556
OpenAlexW4390588985

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.